Nevertheless, our study indicates that targeting SLC6A3/DAT can be useful for cancer research and therapeutics, while the combination with other therapeutics can withdraw synergistic effects with lower doses and less toxicity as much as an independent MoA between the DAT inhibitor and other anticancer medications. This evidence concerns the gene SLC6A3 and cancer.